Company intelligence / Profile preview

ArQule

Norwood, Massachusetts, United Statesmerck.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ArQule’s lead candidate ARQ531 is a novel oral BTK inhibitor showing promise in phase 2 dose expansion studies for difficult-to-treat B-cell malignancies. Miransertib is advancing in registrational trials targeting rare overgrowth syndromes. Derazantinib has orphan drug designation for intrahepatic cholangiocarcinoma. The pipeline reflects precision medicine approaches targeting biomarker-defined patient populations.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecule therapeutics
Industry: Biotech

Drug pipeline

4 assets

ARQ 531

Phase 2

Indications: B-cell malignancies, Chronic lymphocytic leukemia (CLL), Richter's Transformation

3 more assets in the full pipeline.

Request access →

Partnerships

Partnership with Merck post-acquisition to advance oncology pipelineCollaboration on derazantinib development

Beyond the preview

Go deeper on ArQule.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArQule.

Explore the full profile